ReviewBiological psychology2015
Toward a translational approach to targeting the endocannabinoid system in posttraumatic stress disorder: a critical review of preclinical research.
Review in Biological psychology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.BMC psychiatry · 2020Pooled it
- Concurrent Treatment with Prolonged Exposure for Co-Occurring Full or Subthreshold Posttraumatic Stress Disorder and Substance Use Disorders: A Randomized Clinical Trial.Psychotherapy and psychosomatics · 2017Trial
- Understanding the Role of Endocannabinoids in Posttraumatic Stress Disorder.International journal of molecular sciences · 2025Review
- [Comorbidity of posttraumatic stress disorder and addiction from a biopsychosocial perspective].Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater · 2022Article
- Fear extinction learning and anandamide: an fMRI study in healthy humans.Translational psychiatry · 2021Article
- From an Alternative Medicine to a New Treatment for Refractory Epilepsies: Can Cannabidiol Follow the Same Path to Treat Neuropsychiatric Disorders?Frontiers in psychiatry · 2021Review
- Effects of ∆BMC psychiatry · 2020Review
- Sex differences in fear extinction.Neuroscience and biobehavioral reviews · 2019Review
- Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD).Current neuropharmacology · 2019Review
- Prefrontal endocannabinoids, stress controllability and resilience: A hypothesis.Progress in neuro-psychopharmacology & biological psychiatry · 2018Review
- Addictive potential of novel treatments for refractory depression and anxiety.Neuropsychiatric disease and treatment · 2018Review
- Biomarkers for PTSD at the Interface of the Endocannabinoid and Neurosteroid Axis.Frontiers in neuroscience · 2018Article
- Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks.Neuroscience and biobehavioral reviews · 2017Review
- Impact of Cannabis Use on Treatment Outcomes among Adults Receiving Cognitive-Behavioral Treatment for PTSD and Substance Use Disorders.Journal of clinical medicine · 2017Article
- Medical Marijuana and the Treatment of Post Traumatic Stress Disorder: A Survey of Michigan Psychiatrists' Opinions.Spartan medical research journal · 2017Article
- Chronic cannabis use is associated with impaired fear extinction in humans.Journal of abnormal psychology · 2017Article
- Fluoxetine Facilitates Fear Extinction Through Amygdala Endocannabinoids.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016Article
- Cannabidiol as a Potential Treatment for Anxiety Disorders.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2015Review
- Augmentation of Evidence-Based Psychotherapy for PTSD With Cognitive Enhancers.Current psychiatry reports · 2015Review
- Modulation of Fear Extinction by Stress, Stress Hormones and Estradiol: A Review.Frontiers in behavioral neuroscience · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Despite the lack of clinical research, marijuana and synthetic cannabinoids have been approved to treat posttraumatic stress disorder (PTSD) in several states in the United States. This review critically examines preclinical research on the endocannabinoid system (ECS) in order to evaluate three key questions that are relevant to PTSD: (1) Does ECS dysfunction impact fear extinction? (2) Can stress-related symptoms be prevented by ECS modulation? (3) Is the ECS a potential target for enhancing PTSD treatment? Disruption of the ECS impaired fear extinction in rodents, and ECS abnormalities have been observed in PTSD. Targeting fear memories via the ECS had mixed results in rodents, whereas augmented cannabinoid receptor activation typically facilitated extinction. However, the translational value of these findings is limited by the paucity and inconsistency of human research. Further investigation is necessary to determine whether incorporating cannabinoids in treatment would benefit individuals with PTSD, with cautious attention to risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.